- Home
- AMGN vs SBUX Comparison
AMGN vs SBUX Comparison
Compare AMGN & SBUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- SBUX
- Stock Information
- Founded
- AMGN 1980
- SBUX 1971
- Country
- AMGN United States
- SBUX United States
- Employees
- AMGN N/A
- SBUX N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- SBUX Restaurants
- Sector
- AMGN Health Care
- SBUX Consumer Discretionary
- Exchange
- AMGN Nasdaq
- SBUX Nasdaq
- Market Cap
- AMGN 156.2B
- SBUX 127.3B
- IPO Year
- AMGN N/A
- SBUX 1992
- Fundamental
- Price
- AMGN $306.95
- SBUX $97.73
- Analyst Decision
- AMGN Buy
- SBUX Buy
- Analyst Count
- AMGN 21
- SBUX 24
- Target Price
- AMGN $323.26
- SBUX $105.87
- AVG Volume (30 Days)
- AMGN 3.0M
- SBUX 9.8M
- Earning Date
- AMGN 05-01-2025
- SBUX 04-29-2025
- Dividend Yield
- AMGN 3.10%
- SBUX 2.50%
- EPS Growth
- AMGN N/A
- SBUX N/A
- EPS
- AMGN 7.56
- SBUX 3.10
- Revenue
- AMGN $33,424,000,000.00
- SBUX $36,148,700,000.00
- Revenue This Year
- AMGN $7.36
- SBUX $5.88
- Revenue Next Year
- AMGN $2.18
- SBUX $7.02
- P/E Ratio
- AMGN $40.60
- SBUX $31.53
- Revenue Growth
- AMGN 18.57
- SBUX N/A
- 52 Week Low
- AMGN $253.30
- SBUX $71.55
- 52 Week High
- AMGN $346.85
- SBUX $117.46
- Technical
- Relative Strength Index (RSI)
- AMGN 47.38
- SBUX 39.07
- Support Level
- AMGN $304.29
- SBUX $94.77
- Resistance Level
- AMGN $317.58
- SBUX $99.92
- Average True Range (ATR)
- AMGN 5.64
- SBUX 2.27
- MACD
- AMGN -2.39
- SBUX -0.17
- Stochastic Oscillator
- AMGN 13.44
- SBUX 35.97
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About SBUX Starbucks Corporation
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 40,000 stores across more than 80 countries as of the end of fiscal 2024. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.